A study of a liquid biopsy and another looking at tumour mutational burden testing give early indications of Foundation’s approval strategy.
The latest setback to Bristol-Myers Squibb’s first-line lung cancer plan sees it pull its US filing for Opdivo plus Yervoy.
Full results of the Mystic study present a controversial path forward for Imfinzi, and set the stage for the upcoming Neptune trial to be overhauled.
Smaller medtechs saw impressive share price growth in 2018, but not quite as good as the year before.
Cracking the cancer code.
Deciphera Pharmaceuticals emerges as one of the Asco 2018 winner as Jounce Therapeutics falls on weak data.